Company to host in-person and virtual event focused on IPH4502 on November 18, 2026: IPH4502 Phase 1 clinical data and development outlook
Register in-person or virtually
Lacutamab, a first-in-class antibody for cutaneous t-cell lymphoma
More about our lead asset
IPH4502, our Antibody Drug Conjugate targeting Nectin-4
More about this asset
Monalizumab (anti-NKG2A antibody), partnered with AstraZeneca
More about this asset
Collaborating with a strong network to advance our pipeline
Discover our partnering opportunities